Fluoxetine, an inhibitor of serotonin reuptake, was released by the Food and Drug Administration in 1988 and was among the most prescribed drugs for that year. Although fluoxetine has been promoted as a safe antidepressant, a recent literature search revealed a number of case reports of adverse effects and drug interactions attributed to its use. This review familiarizes healthcare professionals with some of the currently known interactions and adverse effects and suggests ways of avoiding such events in clinical practice.
Get full access to this article
View all access options for this article.
References
1.
LowleyGSpringenKLeonardEARobinsKGordonJ. The promise of Prozac. Newsweek March 26, 1990: 38–41.
2.
HornDPreskornSH. Mania during fluoxetine treatment for recurrent depression (letter). Am J Psychiatry1989; 146: 1638–9.
3.
NakraBRSSzwaboPGrossbergGT. Mania induced by fluoxetine (letter). Am J Psychiatry1989; 146: 1515–6.
4.
MandalosGESzarekB. Dose related paranoid reaction associated with fluoxetine (letter). J Nerv Ment Dis1990; 178: 57–8.
5.
KaplanHISadockBJ, eds. Comprehensive textbook of psychiatry. 5th ed. Baltimore: Williams and Wilkins, 1989: 1418.
6.
TeicherMHGoldCColeJO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry1990; 147: 207–10.
7.
BouchardRHPourcherEVincentP. Fluoxetine and extrapyramidal side effects (letter). Am J Psychiatry1989; 146: 1352–3.
CunninghamMCunninghamKLydiardRB. Eye tics and subjective hearing impairment during fluoxetine therapy (letter). Am J Psychiatry1990; 147: 947–8.
23.
TateJ. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry1989; 146: 399–400.
24.
LockJDGwirtsmanHETargEF. Possible adverse drug interactions between fluoxetine and other psychotropics (letter). J Clin Psychopharmacol1990; 10: 383–4.
25.
SommiRCrismonLBowdenC. Fluoxetine: A serotonin-specific, second-generation antidepressant. Pharmacotherapy1987; 7: 1–15.
26.
Drug Facts and comparisons. St. Louis: JB Lippincott, 1989: 2631.
SternbachH. Danger of MAOI therapy after fluoxetine withdrawal. Lancet1988; 2: 850–1.
29.
DentonPHBorelliVMEdwardsNV. Dangers of monoamine oxidase inhibitors. Br Med J1962; 2: 1752–3.
30.
PalmerH. Potentiation of pethidine (letter). Br Med J1960; 2: 944.
31.
ReidNCRWJonesD. Pethidine and phenelzine (letter). Br Med J1962; 1: 408.
32.
TaylorDC. Alarming reaction to pethidine in patients on phenylzine. Lancet1962; 2: 401–2.
33.
VigranIM. Dangerous potentiation of meperidine hydrochloride by pargyline hydrochloride. JAMA1964; 817: 953–4.
34.
FjallandB. Neuroleptic influence on hyperthermia induced by 5-hydroxytryptophan and p-methoxy-amphetamine in MAOI-pretreated rabbits. Psychopharmacology1979; 63: 113–7.
35.
GrahamPIlettK. Danger of MAOI therapy after fluoxetine withdrawal. Lancet1988; 2: 1255–6.
36.
VaughanD. Interaction of fluoxetine with tricyclic antidepressants (letter). Am J Psychiatry1988; 145: 1478.
37.
BellIColeJ. Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression. J Clin Psychopharmacol1988; 8: 447–8.
38.
DownsJMDownsAORosenthalTLDealNAkiskalHS. Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine. J Clin Psychiatry1989; 50: 226–7.
39.
DownsJMDahmerSK. Fluoxetine and elevated plasma levels of tricyclic antidepressants (letter). Am J Psychiatry1990; 147: 1251.
40.
GoodnickPJ. Influence of fluoxetine on plasma levels of desipramine (letter). Am J Psychiatry1989; 146: 552.
41.
PreskornSHBeberJHFaulJCHirschfeldRMA. Serious adverse effects of combining fluoxetine and tricyclic antidepressants (letter). Am J Psychiatry1990; 147: 532.
42.
SkowronDMGutierrezMAEpsteinS. Precaution with titrating nortriptyline after the use of fluoxetine (letter). DICP Ann Pharmacother1990; 24: 1008.
43.
DemasoDRHunterTA. Combining fluoxetine with desipramine (letter). J Am Acad Child Adolesc Psychiatry1990; 29: 151.
44.
KahnDG. Increased plasma nortriptyline concentration in a patient cotreated with fluoxetine (letter). J Clin Psychiatry1990; 51: 36.
45.
AranowRBHudsonJIPopeHAJrElevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry1989; 146: 911–3.
46.
PearsonHJ. Interaction of fluoxetine with carbamazepine (letter). J Clin Psychiatry1990; 51 (3): 126.
47.
SalamaAShafeyM. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate (letter). Am J Psychiatry1989; 146: 278.
48.
NoveskeGFHahnKRFlynnRJ. Possible toxicity of combined fluoxetine and lithium (letter). Am J Psychiatry1989; 146: 1515.
49.
AustinLSAranaGWMelvinJA. Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. J Clin Psychiatry1990; 51: 344–5.
50.
HadleyACasonMP. Mania resulting from lithium-fluoxetine combination (letter). Am J Psychiatry1989; 146: 1637–8.
51.
PopeHJrMcElroySLNixonRA. Possible synergism between fluoxetine and lithium in refractory depression (letter). Am J Psychiatry1988; 145: 1292–3.
52.
SteinerWFontaineR. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: Five case reports. Biol Psychiatry1986; 21: 1067–71.
53.
KlineSMauroLScala-BarnettDZickD. Serotonin syndrome as a cause of death. Clin Pharm1989; 8: 510–4.
54.
WernickeJ. The side effect profile and safety of fluoxetine. J Clin Psychiatiy1985; 46: 59–67.
55.
HansenTEDieterKKeepersGA. Interaction of fluoxetine and pentazocine (letter). Am J Psychiatry1990; 147: 949–50.
56.
BodkinJATeicherMH. Fluoxetine may antagonize the anxiolytic action of buspirone (letter). J Clin Psychopharmacol1989; 9: 150.
57.
TanquaryJMasandP. Paradoxical reaction to buspirone augmentation of fluoxetine (letter). J Clin Psychopharmacol1990; 10: 377.
58.
LembergerLRoweHBosomworthJCTenbargeJBBergstromRF. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther1988; 43: 412–9.
